Global Biological Safety Testing Market Industry: Market Size & Forecast 2026

Biological safety testing involves the evaluation of raw materials, intermediates, and finished biopharmaceutical products to detect and quantify contaminants such as bacteria, fungi, viruses, endotoxins, mycoplasma, and adventitious agents. This testing is a critical quality control step mandated by global health authorities including the U.S. FDA, EMA, and PMDA, ensuring that biologic medicines are safe for human use. The market encompasses both test kits and reagents, such as immunoassays, PCR-based assays, and cell-based assays, as well as outsourced testing services offered by contract research and testing laboratories.

• •Core test types include sterility testing, endotoxin testing, mycoplasma detection, viral safety testing, and residual host cell DNA quantification
• •Applications span vaccines, blood and blood products, cellular and gene therapies, monoclonal antibodies, and recombinant proteins
• •The market serves biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and academic research institutions

The expanding pipeline of biologic drugs, particularly cell and gene therapies, CAR-T treatments, and mRNA-based vaccines, is substantially increasing demand for specialized safety testing at every stage of development and manufacturing. Stringent regulatory frameworks from the FDA, ICH guidelines, and European Pharmacopoeia require increasingly comprehensive safety characterization, compelling manufacturers to invest heavily in validated testing platforms. Additionally, the growing trend of outsourcing non-core functions to specialized contract testing laboratories allows biopharma companies to scale operations without building extensive in-house testing infrastructure.

• •FDA, EMA, and ICH regulations mandate rigorous safety testing protocols for all biologic products, creating sustained baseline demand
• •The rise of personalized medicine and advanced therapies (CAR-T, stem cell therapies, viral vectors) requires novel, more complex safety assessments
• •Biopharmaceutical companies increasingly outsource testing to CROs and contract testing labs to reduce costs and accelerate time-to-market

By product, the market is divided into kits and reagents, including ELISA-based assays, PCR and qPCR kits, cell culture media, and indicator organism strains, and outsourced testing services. By application, vaccine safety testing represents one of the largest segments, driven by global immunization initiatives, while cellular and gene therapy safety testing is the fastest-growing segment. North America currently dominates the market due to its concentration of biopharma headquarters, robust regulatory infrastructure, and high R&D spending, with the United States as the primary contributor.

• •North America leads the market, followed by Europe and the Asia-Pacific region, where China, India, and Japan are expanding their biopharmaceutical manufacturing capacity
• •Test type segmentation includes sterility tests, endotoxin tests, bioburden tests, viral safety tests, and mycoplasma tests
• •The services segment is growing faster than products as CDMOs and biopharma firms increasingly rely on third-party testing laboratories

What are the recent trends and outlook?

Emerging technological trends are reshaping the biological safety testing market, with rapid microbiological methods (RMM), next-generation sequencing (NGS) for viral safety testing, and high-throughput automation gaining significant traction as companies seek to reduce turnaround times and improve test sensitivity. The increasing complexity of biologic modalities, such as lipid nanoparticle-formulated mRNA therapies and viral vector gene therapies, is creating demand for novel testing approaches that can address unique contamination risks. Looking forward, the market is expected to maintain robust growth through the early 2030s, supported by continued expansion of biologic drug approvals, rising biosimilar development activity, and the global build-out of advanced biopharmaceutical manufacturing infrastructure in emerging economies.

• •Next-generation sequencing and rapid microbiological methods are increasingly replacing traditional culture-based assays to shorten testing timelines
• •The growing pipeline of biosimilars requires extensive comparability safety testing against reference biologic products, creating incremental market demand
• •Expansion of biomanufacturing capacity in Asia-Pacific and Latin America is driving localized demand for safety testing services and regulatory-compliant testing products